Reversal of multidrug resistance by phenothiazines and structurally related compounds Avner RamuNili Ramu Original Articles Pages: 165 - 173
Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer James BishopRobin MurrayGary Leber Original Articles Pages: 174 - 178
Antitumor effects ofN-alkylated polyamine analogues in human pancreatic adenocarcinoma models Barbara K. ChangRaymond J. BergeronYayun Liang Original Articles Pages: 179 - 182
Regulatory and antiproliferative effects ofN-alkylated polyamine analogues in human and hamster pancreatic adenocarcinoma cell lines Barbara K. ChangRaymond J. BergeronPaul R. Libby Original Articles Pages: 183 - 188
Dose dependence of the cytokinetic and cytotoxic effects of epirubicin in vitro Detlef BartkowiakJörg HemmerErwin Röttinger Original Articles Pages: 189 - 192
A high-performance liquid chromatographic assay for CI-973, a new anticancer platinum diamine complex, in human plasma and urine ultrafiltrates William W. BullenLarry D. AndressRobert A. Newman Original Articles Pages: 193 - 198
Calculation of received dose intensity for combinations of drugs using small-cell lung carcinoma treatment regimens as examples Galen L. WamplerJohn G. Fryer Original Articles Pages: 199 - 206
Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients Maria J. TassoAlan V. BoddyJeffrey R. Idle Original Articles Pages: 207 - 211
Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small-cell lung cancer Cesare GridelliGiuseppe AiromaAngelo Raffaele Bianco Short Communication Pages: 212 - 214
Doxorubicin and doxorubicinol plasma concentrations and excretion in parotid saliva Françoise BressolleJeanne-Marie JacquetJean-François Rossi Short Communication Pages: 215 - 218
Phase II study of high-dose aclarubicin in previously treated patients with small-cell lung cancer Peter Buhl JensenSusanne Kornum LarsenIrene Stilbo Short Communication Pages: 219 - 220
Pharmacokinetics and tumor concentration of intraarterial and intravenous cisplatin in patients with head and neck squamous cancer Vanna Chiarion SileniVinicio FosserPaola Arslan Short Communication Pages: 221 - 225
Phase I study of Datelliptium chloride, hydrochloride given by 24-h continuous intravenous infusion D. KhayatC. BorelM. Weil Short Communication Pages: 226 - 228
Methylprednisolone as antiemetic treatment in breast-cancer patients receiving cyclophosphamide, methotrexate, and 5-fluorouracil: a prospective, crossover, randomized blind study comparing two different dose schedules Eliahu GezNurith StraussDavid Zvi Edelmann Short Communication Pages: 229 - 232
Simultaneous occurrence of acute myelogenous leukemia and seminoma of the testis Claude LinassierPascale Poumier-GaschardPhilippe Colombat Short Communication Pages: 233 - 234
Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor Ellen FrichePeter Buhl JensenNis I. Nissen Short Communication Pages: 235 - 237
Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing themdr1 phenotype Peter A. W. te BoekhorstJan van KapelPieter Sonneveld Short Communication Pages: 238 - 242
Salvage therapy for non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide, and cisplatin Nissim HaimEdward RosenblattEliezer Robinson Short Communication Pages: 243 - 244
A phase II study of sulofenur, a novel sulfonylurea, in recurrent epithelial ovarian cancer Mary ER O'BrienJanet HardyEve Wiltshaw Short Communication Pages: 245 - 248
Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxatrone (Short communication) L. Thomas VlasveldBabs G. TaalSjoerd Rodenhuis Erratum Pages: 249 - 249
